standardised allergen extract of pollen from white birch betula verrucosa oral lyophilisate (Itulazax 12 SQ-Bet®)

ALK-Abello Ltd

4 February 2022

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation standardised allergen extract of pollen from white birch betula verrucosa (Itulazax 12 SQ-Bet®) is not recommended for use within NHSScotland.

**Indication under review:** In adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. ITULAZAX is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

**Advice context:**

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman**
Scottish Medicines Consortium